We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




AI Tool Helps Make Real-Time Diagnosis During Surgery

By LabMedica International staff writers
Posted on 26 Dec 2022
Print article
Image: Deep-learning model improves image quality of frozen tissue samples to increase accuracy of time-critical pathology diagnostics (Photo courtesy of Pexels)
Image: Deep-learning model improves image quality of frozen tissue samples to increase accuracy of time-critical pathology diagnostics (Photo courtesy of Pexels)

When a patient undergoes a surgical operation to remove a tumor or treat a disease, the course of surgery is often not predetermined. To decide how much tissue needs to be removed, surgeons must know more about the condition they are treating, including a tumor’s margins, its stage and whether a lesion is malignant or benign - determinations that often hinge upon collecting, analyzing, and diagnosing a disease while the patient is on the operating table. When surgeons send samples to a pathologist for examination, both speed and accuracy are of the essence. The current gold-standard approach for examining tissues often takes too long and a faster approach, which involves freezing tissue, can introduce artifacts that can complicate diagnostics. Now, researchers have developed a new method that leverages artificial intelligence to translate between frozen sections and the gold-standard approach, thereby improving the quality of images to increase the accuracy of rapid diagnostics.

For making final diagnoses, pathologists use formalin-fixed and paraffin-embedded (FFPE) tissue samples - this method preserves tissue in a way that produces high-quality images but the process is laborious and typically takes 12 to 48 hours. For a rapid diagnosis, pathologists use an approach known as cryosectioning that involves fast freezing tissue, cutting sections, and observing these thin slices under a microscope. Cryosectioning takes minutes rather than hours but can distort cellular details and compromise or tear delicate tissue. Researchers at the Brigham and Women’s Hospital (Boston, MA, USA) have developed a deep-learning model that can be used to translate between frozen sections and more commonly used FFPE tissue. The team demonstrated that the method could be used to subtype different kinds of cancer, including glioma and non-small-cell lung cancer.

The researchers validated their findings by recruiting pathologists to a reader study in which they were asked to make a diagnosis from images that had gone through the AI method and traditional cryosectioning images. The AI method not only improved image quality but also improved diagnostic accuracy among experts. The algorithm was also tested on independently collected data from Turkey. The researchers note that in the future, prospective clinical studies should be conducted to validate the AI method and determine if it can contribute to diagnostic accuracy and surgical decision-making in real hospital settings.

“We are using the power of artificial intelligence to address an age-old problem at the intersection of surgery and pathology,” said corresponding author Faisal Mahmood, PhD, of the Division of Computational Pathology at BWH. “Making a rapid diagnosis from frozen tissue samples is challenging and requires specialized training, but this kind of diagnosis is a critical step in caring for patients during surgery.”

“Our work shows that AI has the potential to make a time-sensitive, critical diagnosis easier and more accessible to pathologists,” said Mahmood. “And it could potentially be applied to any type of cancer surgery. It opens up many possibilities for improving diagnosis and patient care.”

Related Links:
Brigham and Women’s Hospital

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.